morn dplo announc postpon ep report previous
schedul monday feb due recent determin
need record non-cash impair charg relat pbm busi
castiarx predic reduc financi forecast busi
note revenu total adj ebitda impact
impair charg outlook remain unchang addit
dplo withdrew preliminari full-year outlook provid
jan guid falter fledgl pbm segment predic
weak pbm specialti segment call question
dplo longer term growth trajectori strategi dplo provid
updat outlook report result date tbd
maintain ep estim earli junctur howev lower
tp ebitda prior inher
lower convict earn growth prospect
share sink despit recent weak share dplo share fall
recent updat weak pbm segment
even wors fear compound new troublesom updat relat
specialti busi growth driver moreov recent
updat provid real sens clariti extent expect
preliminari guidanc shortfal unquantifi said longer term
view dplo well posit vertic integr landscap
potenti traction middle-market account well path scale
pbm offer albeit clearli longer term phenomenon risk shift
demand regulatori factor integr headwind
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
diplomat pharmaci independ specialti pharmaci
dispens pharmaceut patient complex chronic
price feb rate neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario predic acceler
integr recent acquir pbm accompani earlier
expect execut cost synergi cross-sel
acceler de-lever allow dplo resum acquisit
strategi earlier expect strategi mind potenti
diversifi suppli chain acquir could like
grey sky scenario predic unexpect
slowdown specialti pharmaceut industri
regulatory/reimburs shift integr miscu
 close
dplo withdrew preliminari guidanc weaker expect across
specialti pharmaci pbm segment base materi lower januari result
expect intern dplo notifi anoth custom loss pbm busi
conjunct softer outlook custom win factor led
lower outlook pbm busi meanwhil specialti busi dplo
acknowledg increasingli aggress member channel manag techniqu
implement larger integr competitor express script accredo
reduc pharmaci script volum also note less favor drug mix within certain
payer contract weigh profit
compani mention price
